Literature DB >> 20805711

[Novel influenza A (H1N1) infection in immunocompromised patients].

Kwan Yong Seo1, Hyun Chul Lee, Yu Kyung Kim, Won Kil Lee, Kyung Eun Song.   

Abstract

BACKGROUND: Since April 2009, novel influenza A (H1N1) infection is spreading throughout the world. This infection might be fatal for immunocompromised patients who are at a potentially high risk of developing infectious complications. We investigated the detection rate and features of H1N1 infection in immunocompromised patients.
METHODS: Between August 2009 and February 2010, we examined 8,112 subjects, including 390 immunocompromised patients, for H1N1. Swab samples were taken from the nose and throat of the participants. Real-time PCR was performed to identify H1N1 viral genes.
RESULTS: Positive results were obtained in 2,953/8,112 (36.4%) subjects and 46/390 (11.8%) immunocompromised patients. H1N1 was identified in 8.7% patients with solid cancer, 12.9% patients with hematologic malignancy, 16.7% patients with chronic renal disease, and 14.5% patients with kidney transplantation. The mean cycle threshold (Ct) value of PCR was significantly lower (P<0.05) in patients with hematologic malignancy as compared to that in patients with chronic renal disease and control subjects. Four patients died due to respiratory complications.
CONCLUSIONS: The detection rate of H1N1 was significantly lower in immunocompromised patients than in other patients. The Ct value of patients with hematologic malignancy was significantly lower than that of other immunocompromised patients and control subjects.

Entities:  

Mesh:

Year:  2010        PMID: 20805711     DOI: 10.3343/kjlm.2010.30.4.388

Source DB:  PubMed          Journal:  Korean J Lab Med        ISSN: 1598-6535


  1 in total

1.  Prevalence of seasonal influenza viruses and pandemic H1N1 virus in Beijing from 2008 to 2012.

Authors:  Shujuan Cui; Lili Tian; Xiaomin Peng; Guilan Lu; Weixian Shi; Dongmei Meng; Quanyi Wang
Journal:  Ann Lab Med       Date:  2012-10-17       Impact factor: 3.464

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.